Please find attached intimation regarding re-affirmation/withdrawl of Credit Rating by CRISIL

October 29, 2026 BSE Limited National Stock Exchange of India Limited P J Towers, Exchange Plaza, C-1, Block G, Dalal Street, Bandra Kurla Complex, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 543904 Symbol: MANKIND Dear Sir/ Madam, Subject: Intimation regarding re-affirmation/withdrawal of Credit Rating-CRISIL Ref.: Regulation 30 & 51 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) Pursuant to Regulations 30 and 51 read with Schedule III of the Listing Regulations, we wish to inform you that CRISIL Ratings Limited (“CRISIL”) vide its release dated October 29, 2026 has reaffirmed/withdrawn the credit rating for the following instruments of the Company: Instruments Amount Rating Rating (₹ in crore) Action Non-Convertible Debentures 40 0 Crisil AA+/Stable Reaffirmed Non-Convertible Debentures 2,100 Crisil AA+/Stable Reaffirmed Non-Convertible Debentures 2,500 Crisil AA+/Stable Withdrawn Commercial Paper 1,500 Crisil A1+ Withdrawn The detailed rationale provided by the CRISIL can be accessed by clicking on the link: Rating Rationale The above information is also available on the website of the Company at www.mankindpharma.com. This is for your information and records. Thanking You, Yours Faithfully, For Mankind Pharma Limited Hitesh Kumar Jain Company Secretary & Compliance Officer